A Study Of Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

A Phase 1B Inpatient, Randomized, Double-Blind, Placebo-Controlled, Crossover Study Of The Safety And Efficacy Of Two Fixed Doses Of PF-3463275 In Adjunctive Treatment Of Cognitive Deficits In Schizophrenia

The objective of this study is to evaluate the safety, tolerability, and efficacy of two dose regimens of PF-3463275 compared with placebo added to ongoing atypical antipsychotic therapy for cognitive deficits in subjects with chronic symptoms of schizophrenia.

Inclusion Criteria:

• Diagnosis of schizophrenia
• In stable treatment with risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, or paliperidone for at least 2 months
• Stable symptoms of schizophrenia for at least 3 months.

Exclusion Criteria:

• Subjects with a psychiatric disorder other than schizophrenia
• Substance dependence or abuse
• Women who have child bearing potential.